Saratov JOURNAL of Medical and Scientific Research

Characteristics of COVID-19 associated coagulopathy in real clinical practice

Year: 2021, volume 17 Issue: №3 Pages: 541-547
Heading: Тhematic supplement Article type: Original article
Authors: Malinova L.I., Krasnikova V.V., Krivets A.S., Radzhabov H.M., Furman N.V. Reshetnikov A.A., Dolotovskaya P.V.
Organization: Saratov Regional Clinical Cardiological Centre, Saratov State Medical University

Purpose: to perform a comparative analysis of the hemostasis state in patients with a SARS-CoV-2 infection (CO-VID-19) hospitalized in the intensive care unit (ICU). Material and Methods. The retrospective analysis of the medical data of patients with COVID-19 (n=105), admitted to ICU in the «COVID hospital», consisted of the following: complete blood count test; screening global clotting tests routinely performed at admission (activated partial thromboplastin time (APTT), prothrombin index, international normalized index, fibrinogen). Results. We detected sex differences in COVID-19 patients referring hemoglobin level (lower in women, p<0.05) and thrombocytopenia rates (more often in men, p=0.032). There were moderately strong negative correlations between the duration of hospitalization and the leukocytes count at admission (R=0.410; p=0.037), platelet count at admission (R=0.402; p=0.046). In COVID-19 patients we detected increased fibrinogen with a normal or slightly lower platelet count, and normal or slightly increased prothrombin time and APTT. Conclusion. The major coagulation parameters associated with COVID-19 are increased fibrinogen with a normal or slightly lower platelet count, and normal or slightly increased prothrombin time and APTT. COVID-19 associated coagulopathy is characterized by sex differences, which partly determines the specifics of the clinical course of the disease in men and women patients.

1. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020; 127: 104362.
2. Belen-Apak FB, Sarialioglu F. The old but new: can unfractionated heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV-2 by inhibition of host cell proteases? Med Hypotheses 2020; 142:109743.
3. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180: 934-43.
4. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-20.
5. LiaoD,ZhouF, LuoL,etal. Haematologicalcharacteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 2020; 7:e671-8.
6. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Targeted Therapy 2020; 5: 1-3.
7. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019; 133:906-18.
8. Haitao T, Vermunt JV, Abeykoon J, et al. COVID-19 and Sex Differences: Mechanisms and Biomarkers. Mayo Clin Proc 2020; 95 (10): 2189-203. DOI: 10.1016/j.mayocp.2020.07.024.
9. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58: 1116-20.
10. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020; 120: 998-1000.
11. Panigada M, Bottino N, Tagiabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18: 1738-42.
12. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020; 95: 834-47.
13. Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020; 95: E131-E134.
14. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clinica Chimica Acta 2020; 506:145-8.
15. Llitjos J-F, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18: 1743-6.
16. Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 2020; 18: 1469-72.
17. Asirvatham ES, Sarman CJ, Saravanamurthy SP, et al. Who is dying from COVID-19 and when? An Analysis of fatalities in Tamil Nadu, India. Clinical Epidemiology and Global Health 2021;9:275-9. Doi: 10.1016/j.cegh.2020.09.010.
18. Schulman S. COVID-19, prothrombotic factors and venous thromboembolism. Semin Thromb Hemost 2020. DOI: 10.1055/S-0040-1710337.
19. Kwaan HO Coronavirus disease 2019: the role of the fibrinolytic system from transmission to organ injury and sequelae. Semin Thromb Hemost 2020; May 9. DOI: 10.1055/s-0040-1709996.
20. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin aldosterone system and thrombosis. J Clin Invest 1995; 95: 995-1001.

2021_03-1_541-547.pdf594.88 KB

No votes yet